Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Roche

Status and phase: Terminated; Phase 2

Conditions: Autoimmune Hepatitis; Autoimmune Chronic Hepatitis

Treatments: Drug: RO7049665; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04790916

2020-003990-23 (EudraCT Number)

BP42698

Details and patient eligibility

About

The primary objective of the study is to evaluate the effect of RO7049665 on time to relapse following forced corticosteroid (CCS) tapering as measured by the hazard ratio between RO7049665 7.5 milligrams (mg) and placebo arm.

Enrollment: 2 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with a definite diagnosis of AIH (type 1, 2 and 3) as per simplified or revised original diagnostic criteria
• Participants who have been in biochemical remission for > 2 years (or less if according to the local practice) prior to randomization
• Participants who have been on stable treatment (corticosteroids [CCSs] +/- non-specific immunosuppressants [NSIs]) for at least 3 months prior to randomization and who have not had a dose increase in the previous 6 months prior to randomization
• No signs of liver inflammation on a liver biopsy taken no more than 12 months prior to randomization
• Participants with AIH who have previously not attempted (or not attempted in the last 3 years, if this is the local practice) to taper CCSs to 0 mg/day
• Body mass index within the range of 18-35 kilograms per meter square (kg/m^2)
• Women of childbearing potential who agree to remain abstinent or use at least one acceptable contraceptive method during the treatment period and for at least 28 days after the final dose of study drug

Exclusion criteria

• Participants with cirrhosis (F4 fibrosis by Fibroscan®) with significant impairment of liver function (Child Pugh category B or C)
• Any other autoimmune disease requiring immunomodulating treatment
• History of infection with hepatitis B, human immunodeficiency virus, active hepatitis C virus (HCV) infection, detection of replicating cytomegalovirus (CMV) or Epstein-Barr virus (EBV)
• Active infections requiring systemic therapy with antibiotic, antiviral, or antifungal treatment or febrile illness within 7 days before Day-1
• History of primary or acquired immunodeficiency
• Pregnant or lactating female participants
• Symptomatic herpes zoster within 3 months prior to screening
• History of active or latent tuberculosis or a positive Quantiferon Gold test
• History of clinically significant severe drug allergies, multiple drug allergies, allergy to any constituent of the product, or intolerance to topical steroids
• Lymphoma, leukemia, or any malignancy within the past 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years and in situ carcinoma of the cervix that was completely removed surgically. Breast cancer within the past 10 years
• Significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
• Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator
• CCSs of <5 mg/day, or <2.5 mg CCSs plus immune suppressant, or <3 mg/day budesonide with or without immune suppressant
• CCSs >20 mg/day or >9 mg/day budesonide
• Non-specific immunosuppressant (NSI) daily dose higher than recommended standard of care therapy
• T or B cell-depleting therapy within the last 12 months or T- or B-cell number below normal due to depleting therapy
• Leukocyte apheresis within 12 weeks of screening
• Donation of blood or blood products in excess of 500 milliliters (mL) within 3 months prior to screening.
• Exposure to any investigational treatment within 6 months prior to Day 1
• Abnormal hematologic, hepatic enzyme, hepatic function, or biochemistry values

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

2 participants in 3 patient groups, including a placebo group

RO7049665 3.5 mg

Experimental group

Description:

Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed.

Treatment:

Drug: RO7049665

RO7049665 7.5 mg

Experimental group

Description:

Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed.

Treatment:

Drug: RO7049665

Placebo

Placebo Comparator group

Description:

Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.

Treatment:

Other: Placebo